All posts related to "rheumatoid arthritis"

The NIH has awarded $6 million to arthritis research

AMP Program Word CloudThe National Institute of Health (NIH) has awarded 11 grants (a total of $6 million) to members of the Accelerating Medicines Partnership in Rheumatoid Arthritis and Lupus (AMP RA/Lupus) Network. The alliance includes various private and public research groups across the United States who are committed to advance research on rheumatoid arthritis (RA) and lupus drugs.

AMP RA/Lupus hope to identify and test biologic agents for RA and lupus treatment. Researchers believe that the disease similarities for RA and lupus will allow them to study both diseases at the same time.

Continue reading

Spotlight on Arthritis Superheroes

SuperheroesToday, the “Spotlight on Arthritis Superheroes” is directed on Rheumatoid Arthritis Guy.

RA Guy’s rheumatoid arthritis started when he was in his 20’s. His heels were in pain and his knees creaked. In the winter time, his RA symptoms became worse. In his 30’s, his pain never went away and he was unable to use his knees. Finally, after many visits to a doctor, he came across a rheumatologist who confirmed that he had rheumatoid arthritis.

Since his diagnosis, RA Guy has learned a lot about rheumatoid arthritis.

“I learned what TENS means. I gained weight. I regained the use of my knees. I got on meds. I got off meds. I got back on meds. I started doing yoga. I lost a lot of weight. I started taking hot baths. I started sleeping with wool socks. I started taking lots of NSAIDs. I started having stomach problems. I got depressed. I started wearing ankle braces. I started wearing wrist braces. I got happy. I started meditating. I started writing positive affirmations. I started pacing myself through my day-to-day activities. I went into remission. I came out of remission. I had lots of flares. I started therapy. I started getting early joint damage. I started this blog. Most importantly, I started to learn how to LIVE with rheumatoid arthritis.”

Join RA Guy as he shares his ups and downs and continues his journey through chronic pain and debilitating inflammation. Our favourite part about his blogs is that he uses humor to shed light onto matters that others may consider serious. Continue reading

September 10 is World Suicide Prevention Day

World Suicide Prevention Day BannerSeptember 10 is World Suicide Prevention Day. Statistics Canada reports that in 2009 alone, there were about 100,000 years of potential life lost to Canadians under the age of 75 as a result of suicides. Suicide is a major cause of premature and preventable death.

The Statistics Canada website states:

Research shows that mental illness is the most important risk factor for suicide; and that more than 90% of people who commit suicide have a mental or addictive disorder. Depression is the most common illness among those who die from suicide, with approximately 60% suffering from this condition. No single determinant, including mental illness, is enough on its own to cause a suicide. Rather, suicide typically results from the interaction of many factors, for example: mental illness, marital breakdown, financial hardship, deteriorating physical health, a major loss, or a lack of social support.

People living with rheumatoid arthritis (RA) are twice as likely as the rest of the population to experience depression. The following are possible reasons depression occurs in people with RA:

Continue reading

JointHealth™ monthly: Having summer fun with arthritis

JointHealth monthly Title PageJointHealth™ monthly: Having summer fun with arthritis

The key ingredients to a healthy dose of summer fun include taking care of your body by eating well, maintaining a healthy body weight, adhering to your treatment therapy, and doing the right kinds of exercise properly.

In this issue of JointHealth™ monthly, you will find out the benefits of outdoor summer exercise for people living with arthritis and learn ways in which people living with arthritis can enjoy summer. As well, you will learn:

  • How to play tennis or golf safely with arthritis.
  • How you can optimize your biking experience.
  • What you can do to minimize pain when travelling, camping, or hiking with arthritis.
  • Which beach and poolside books or films offer insights into living with arthritis.
  • How you can help raise awareness for arthritis during Arthritis Awareness Month in Canada in September by downloading the ArthritisID and ArthritisID PRO apps.

Call for patient input on subsequent entry biologic infliximab (Remsima™ and Inflectra™)

Call for patient input on subsequent entry biologic infliximab (Remsima™ and Inflectra™) for ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, and/or rheumatoid arthritis

Megaphone GraphicDo you have ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, and/or rheumatoid arthritis or care for someone who does? We need your valuable input.

Health Canada defines subsequent entry biologics (SEBs) as biologic medicines that are similar to, and would enter the market after an approved innovator biologic (such as Remicade®). 

Unlike the more common small-molecule drugs, biologics generally exhibit high molecular complexity, and are sensitive to changes in manufacturing practices. SEBs are not identical to their innovator products because their chemical characteristics cannot be precisely duplicated during the manufacturing process. Therefore, SEBs may have unique efficacy, immunogenicity, and safety profiles that are different from their innovator products.
Continue reading

Reminder: Patient input on treatment for rheumatoid arthritis and ankylosing spondylitis needed

Metal Alarm ClockDo you have rheumatoid arthritis or ankylosing spondylitis or care for someone who does? We want your valuable input.

In July, Arthritis Consumer Experts sent out the following JointHealth™ expresses announcing that we are gathering patient input to submit to the Common Drug Review (CDR). Follow the links below to view the questions for each patient input request.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec). 

To help them make their recommendations, the CDR accepts input from patient groups, like Arthritis Consumer Experts (ACE). We would like to gather your views and share them with the CDR.

If you live with rheumatoid arthritis or ankylosing spondylitis or care for someone with the disease, please send us your input by Wednesday, August 20, 2014, so that we may submit a report by the August 28 deadline. Your input will be anonymous.

Please contact us at to provide your input or arrange for a phone interview at 604-974-1366.